BREAKOUT CUP WITH HANDLE AND HIGH VOLUM BUY CTLT ABOUT 93.66$
Catalent (CTLT) has contracts to make three of the leading Covid-19 vaccine candidates.
In the company's June-quarter earnings release early Monday, CEO John Chiminski said a shift to more innovative technologies is "reflected in more than 50 Covid-19-related program wins."
Among other gains, Chiminski said Catalent has built its cash position to more than $950 million, "positioning us to continue our growth investments."
OPERATING INCOME 11% ABOUT
1% CAPITAL
In the company's June-quarter earnings release early Monday, CEO John Chiminski said a shift to more innovative technologies is "reflected in more than 50 Covid-19-related program wins."
Among other gains, Chiminski said Catalent has built its cash position to more than $950 million, "positioning us to continue our growth investments."
OPERATING INCOME 11% ABOUT
1% CAPITAL
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.